Skip to main content
SpringerLink
Log in

Comparative Effectiveness in Hepatic Malignancies

  • Chapter
  • First Online:
Comparative Effectiveness in Surgical Oncology

Part of the book series: Cancer Treatment and Research ((CTAR,volume 164))

Abstract

The benefits of applying comparative effectiveness research (CER) strategies to the management of cancer are important. As the incidence of cancer increases both in the United States and worldwide, accurate analysis of which tests and treatments should be applied in which situations is critical, both in terms of measurable and meaningful clinical outcomes and health care costs. In the last 20 years alone, multiple controversies have arisen in the diagnosis and treatment of primary and metastatic tumors of the liver, making the management of liver malignancies a prime example of CER. Contributing factors to the development of these controversies include improvements in molecular characterization of these diseases and technological advances in surgery and radiology. The relative speed of these advances has outpaced data from clinical trials, in turn making robust data to inform clinical practice lacking. Indeed, many of the current treatment recommendations for the management of liver malignancies are based primarily on retrospective data. We herein review select CER issues concerning select decision-making topics in the management of liver malignancies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. El-Serag HB, Mason AC (1999) Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340(10):745–750

    CAS  PubMed  Google Scholar 

  2. Yang JD, Roberts LR (2010) Hepatocellular carcinoma: a global view. Nat Rev Gastroenterol Hepatol 7(8):448–458

    PubMed Central  PubMed  Google Scholar 

  3. Bruix J, Sherman M, Llovet JM et al (2001) Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 35(3):421–430

    CAS  PubMed  Google Scholar 

  4. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS (1999) Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 210(3):655–661

    CAS  PubMed  Google Scholar 

  5. Lencioni RA, Allgaier H-P, Cioni D et al (2003) Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection1. Radiology 228(1):235–240

    PubMed  Google Scholar 

  6. Lin S, Lin C, Lin C, Hsu C, Chen Y (2005) Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 54(8):1151–1156

    PubMed Central  CAS  PubMed  Google Scholar 

  7. Caturelli E, Siena DA, Fusilli S et al (2000) Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue—long-term prospective study 1. Radiology 215(1):123–128

    CAS  PubMed  Google Scholar 

  8. Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G (2006) Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol 16(3):661–669

    PubMed  Google Scholar 

  9. Livraghi T (2003) Radiofrequency ablation, PEIT, and TACE for hepatocellular carcinoma. J Hepato-Biliary-Pancreatic Surg 10(1):67–76

    Google Scholar 

  10. d’Etude G, Hépatocellulaire TDC (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256–1261

    Google Scholar 

  11. Lin D, Liaw Y, Lee T, Lai C (1988) Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma—a randomized controlled trial. Gastroenterology 94(2):453–456

    CAS  PubMed  Google Scholar 

  12. Pelletier G, Roche A, Ink O et al (1990) A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 11(2):181–184

    CAS  PubMed  Google Scholar 

  13. Madden M, Krige J, Bailey S et al (1993) Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma. Gut 34(11):1598–1600

    PubMed Central  CAS  PubMed  Google Scholar 

  14. Llovet JM, Fuster J, Bruix J (1999) Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30(6):1434–1440

    CAS  PubMed  Google Scholar 

  15. Llovet JM, Real MI, Montaña X et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734–1739

    PubMed  Google Scholar 

  16. Sergio A, Cristofori C, Cardin R et al (2008) Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 103(4):914–921

    PubMed  Google Scholar 

  17. Pinter M, Hucke F, Graziadei I et al (2012) Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology 263(2):590–599

    PubMed  Google Scholar 

  18. Becker G, Soezgen T, Olschewski M, Laubenberger J, Blum HE, Allgaier H-P (2005) Combined TACE and PEI for palliative treatment of unresectable hepatocellular carcinoma. World J Gastroenterol 11(39):6104

    PubMed  Google Scholar 

  19. Bhagat N, Reyes DK, Lin M, et al. (2013) Phase II study of chemoembolization with drug-eluting beads in patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Intervent Radiol: 1–11

    Google Scholar 

  20. Miller A, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47(1):207–214

    CAS  PubMed  Google Scholar 

  21. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92(3):205–216

    CAS  PubMed  Google Scholar 

  22. Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48:S20–S37

    CAS  PubMed  Google Scholar 

  23. Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53(3):1020–1022

    PubMed Central  PubMed  Google Scholar 

  24. Chen M-S, Li J-Q, Zheng Y et al (2006) A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243(3):321

    PubMed Central  PubMed  Google Scholar 

  25. Huang J, Yan L, Cheng Z et al (2010) A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg 252(6):903–912

    PubMed  Google Scholar 

  26. Qian G-J, Wang N, Shen Q et al (2012) Efficacy of microwave versus radiofrequency ablation for treatment of small hepatocellular carcinoma: experimental and clinical studies. Eur Radiol 22(9):1983–1990

    PubMed  Google Scholar 

  27. Merion RM, Pelletier SJ, Goodrich N, Englesbe MJ, Delmonico FL (2006) Donation after cardiac death as a strategy to increase deceased donor liver availability. Ann Surg 244(4):555

    PubMed Central  PubMed  Google Scholar 

  28. Earl TM, Chapman WC (2013) Hepatocellular carcinoma: resection versus transplantation. In: Seminars in liver disease. Thieme Medical Publishers, Stuttgart, pp 282–292

    Google Scholar 

  29. Yao F, Xiao L, Bass N, Kerlan R, Ascher N, Roberts J (2007) Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 7(11):2587–2596

    CAS  PubMed  Google Scholar 

  30. Mazzaferro V, Regalia E, Doci R et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334(11):693–700

    CAS  PubMed  Google Scholar 

  31. Yao F (2008) Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant 8(10):1982–1989

    CAS  PubMed  Google Scholar 

  32. Belghiti J, Durand F (2011) Criteria for liver transplantation for hepatocellular carcinoma: what is an acceptable outcome? Liver Int 31(s1):161–163

    PubMed  Google Scholar 

  33. Margarit C, Escartín A, Castells L, Vargas V, Allende E, Bilbao I (2005) Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. Liver Transpl 11(10):1242–1251

    PubMed  Google Scholar 

  34. Poon RT, Fan ST, Lo CM, Liu CL, Wong J (2007) Difference in tumor invasiveness in cirrhotic patients with hepatocellular carcinoma fulfilling the Milan criteria treated by resection and transplantation: impact on long-term survival. Ann Surg 245(1):51

    PubMed Central  PubMed  Google Scholar 

  35. Figueras J, Jaurrieta E, Valls C et al (2000) Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. J Am Coll Surg 190(5):580–587

    CAS  PubMed  Google Scholar 

  36. Del Gaudio M, Ercolani G, Ravaioli M et al (2008) Liver transplantation for recurrent hepatocellular carcinoma on cirrhosis after liver resection: University of Bologna experience. Am J Transplant 8(6):1177–1185

    PubMed  Google Scholar 

  37. Koniaris LG, Levi DM, Pedroso FE et al (2011) Is surgical resection superior to transplantation in the treatment of hepatocellular carcinoma? Ann Surg 254(3):527–538

    PubMed  Google Scholar 

  38. Bellavance EC, Lumpkins KM, Mentha G et al (2008) Surgical management of early-stage hepatocellular carcinoma: resection or transplantation? J Gastrointest Surg 12(10):1699–1708

    PubMed  Google Scholar 

  39. Belghiti J, Cortes A, Abdalla EK et al (2003) Resection prior to liver transplantation for hepatocellular carcinoma. Ann Surg 238(6):885

    PubMed Central  PubMed  Google Scholar 

  40. Poon RT-P, Fan ST, Lo CM, Liu CL, Wong J (2002) Long-term survival and pattern of recurrence after resection of small hepatocellular carcinoma in patients with preserved liver function: implications for a strategy of salvage transplantation. Ann Surg 235(3):373–382

    PubMed Central  PubMed  Google Scholar 

  41. Belghiti J, Carr B, Greig P, Lencioni R, Poon R (2008) Treatment before liver transplantation for HCC. Ann Surg Oncol 15(4):993–1000

    CAS  PubMed  Google Scholar 

  42. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230(3):309

    PubMed Central  CAS  PubMed  Google Scholar 

  43. Tzeng C-WD, Aloia TA (2013) Colorectal liver metastases. J Gastrointest Surg 17(1):195–202

    PubMed  Google Scholar 

  44. Mansour J, Fong Y (2007) Timing of the liver resection for patients with synchronous metastases: practical and outcome considerations. Ann Surg Oncol 14(9):2435–2436

    PubMed  Google Scholar 

  45. Khajanchee YS, Hammill CW, Cassera MA, Wolf RF, Hansen PD (2011) Hepatic resection vs minimally invasive radiofrequency ablation for the treatment of colorectal liver metastases: a Markov analysis. Arch Surg 146(12):1416

    PubMed  Google Scholar 

  46. Kopetz S, Chang GJ, Overman MJ et al (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27(22):3677–3683

    PubMed Central  PubMed  Google Scholar 

  47. Saltz LB, Clarke S, Díaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26(12):2013–2019

    CAS  PubMed  Google Scholar 

  48. Narayanan G, Barbery K, Suthar R, Guerrero G, Arora G (2013) Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer. Anticancer Res 33(5):2077–2083

    CAS  PubMed  Google Scholar 

  49. Martin RC, Joshi J, Robbins K, Tomalty D, O’Hara R, Tatum C (2009) Transarterial chemoembolization of metastatic colorectal carcinoma with drug-eluting beads, irinotecan (DEBIRI): multi-institutional registry. J Oncol 2009:539795

    Google Scholar 

  50. Mulier S, Miao Y, Mulier P et al (2005) Electrodes and multiple electrode systems for radiofrequency ablation: a proposal for updated terminology. Eur Radiol 15(4):798–808

    PubMed  Google Scholar 

  51. Goldberg SN, Hahn PF, Tanabe KK et al (1998) Percutaneous radiofrequency tissue ablation: does perfusion-mediated tissue cooling limit coagulation necrosis? J Vasc Interv Radiol 9(1):101–111

    CAS  PubMed  Google Scholar 

  52. Abdalla EK, Vauthey J-N, Ellis LM et al (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239(6):818

    PubMed Central  PubMed  Google Scholar 

  53. Mulier S, Ruers T, Jamart J, Michel L, Marchal G, Ni Y (2009) Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial? Dig Surg 25(6):445–460

    Google Scholar 

  54. Mulier S, Ni Y, Jamart J, Ruers T, Marchal G, Michel L (2005) Local recurrence after hepatic radiofrequency coagulation: multivariate meta-analysis and review of contributing factors. Ann Surg 242(2):158–171

    PubMed Central  PubMed  Google Scholar 

  55. Gillams A, Lees W (2009) Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 19(5):1206–1213

    CAS  PubMed  Google Scholar 

  56. Siperstein AE, Berber E, Ballem N, Parikh RT (2007) Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 246(4):559–567

    PubMed  Google Scholar 

  57. Wicherts DA, Miller R, de Haas RJ et al (2008) Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann Surg 248(6):994–1005

    PubMed  Google Scholar 

  58. Ruers T, Punt C, Van Coevorden F et al (2012) Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol 23(10):2619–2626

    PubMed Central  CAS  PubMed  Google Scholar 

  59. Kemeny N, Daly J, Oderman P et al (1984) Hepatic artery pump infusion: toxicity and results in patients with metastatic colorectal carcinoma. J Clin Oncol 2(6):595–600

    CAS  PubMed  Google Scholar 

  60. Hohn DC, Stagg RJ, Friedman MA et al (1989) A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 7(11):1646–1654

    CAS  PubMed  Google Scholar 

  61. Chang AE, Schneider PD, Sugarbaker PH, Simpson C, Culnane M, Steinberg SM (1987) A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206(6):685

    PubMed Central  CAS  PubMed  Google Scholar 

  62. Lorenz M, Müller H-H (2000) Randomized, multicenter trial of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic arterial infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 18(2):243

    CAS  PubMed  Google Scholar 

  63. Kemeny NE, Niedzwiecki D, Hollis DR et al (2006) Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol 24(9):1395–1403

    CAS  PubMed  Google Scholar 

  64. Fiorentini G, Aliberti C, Tilli M et al (2012) Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 32(4):1387–1395

    CAS  PubMed  Google Scholar 

  65. Martin RC II, Scoggins CR, Tomalty D et al (2012) Irinotecan drug-eluting beads in the treatment of chemo-naive unresectable colorectal liver metastasis with concomitant systemic fluorouracil and oxaliplatin: results of pharmacokinetics and phase I trial. J Gastrointest Surg 16(8):1531–1538

    PubMed  Google Scholar 

  66. Martin RC, Joshi J, Robbins K et al (2011) Hepatic intra-arterial injection of drug-eluting bead, irinotecan (DEBIRI) in unresectable colorectal liver metastases refractory to systemic chemotherapy: results of multi-institutional study. Ann Surg Oncol 18(1):192–198

    PubMed  Google Scholar 

  67. Gray B, Van Hazel G, Hope M et al (2001) Randomised trial of SIR-Spheres® plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol 12(12):1711–1720

    CAS  PubMed  Google Scholar 

  68. Cosimelli M, Golfieri R, Cagol P et al (2010) Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 103(3):324–331

    PubMed Central  CAS  PubMed  Google Scholar 

  69. Nordlinger B, Guiguet M, Vaillant JC et al (1996) Surgical resection of colorectal carcinoma metastases to the liver: a prognostic scoring system to improve case selection, based on 1568 patients. Cancer 77(7):1254–1262

    CAS  PubMed  Google Scholar 

  70. Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM (2004) Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 240(3):438

    PubMed Central  PubMed  Google Scholar 

  71. Berber E, Flesher N, Siperstein AE (2002) Laparoscopic radiofrequency ablation of neuroendocrine liver metastases. World J Surg 26(8):985–990

    PubMed  Google Scholar 

  72. Oshowo A, Gillams A, Harrison E, Lees W, Taylor I (2003) Comparison of resection and radiofrequency ablation for treatment of solitary colorectal liver metastases. Br J Surg 90(10):1240–1243

    CAS  PubMed  Google Scholar 

  73. Aloia TA, Vauthey J-N, Loyer EM et al (2006) Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 141(5):460–467

    PubMed  Google Scholar 

  74. White R, Avital I, Sofocleous C et al (2007) Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis. J Gastrointest Surg 11(3):256–263

    CAS  PubMed  Google Scholar 

  75. Berber E, Tsinberg M, Tellioglu G, Simpfendorfer CH, Siperstein AE (2008) Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. J Gastrointest Surg 12(11):1967–1972

    PubMed  Google Scholar 

  76. Lee W-S, Yun SH, Chun H-K et al (2008) Clinical outcomes of hepatic resection and radiofrequency ablation in patients with solitary colorectal liver metastasis. J Clin Gastroenterol 42(8):945–949

    PubMed  Google Scholar 

  77. Hur H, Ko YT, Min BS et al (2009) Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 197(6):728–736

    PubMed  Google Scholar 

  78. Aloia TA, Vauthey J-N, Loyer EM et al (2006) Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 141(5):460

    PubMed  Google Scholar 

  79. Tsai S, Pawlik TM (2009) Outcomes of ablation versus resection for colorectal liver metastases: are we comparing apples with oranges? Ann Surg Oncol 16(9):2422–2428

    PubMed  Google Scholar 

  80. Gleisner AL, Choti MA, Assumpcao L, Nathan H, Schulick RD, Pawlik TM (2008) Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg 143(12):1204

    PubMed  Google Scholar 

  81. Wong SL, Mangu PB, Choti MA et al (2010) American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 28(3):493–508

    PubMed  Google Scholar 

  82. Goldberg RM, Sargent DJ, Morton RF et al (2004) A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22(1):23–30

    CAS  PubMed  Google Scholar 

  83. Vauthey J-N, Pawlik TM, Ribero D et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24(13):2065–2072

    CAS  PubMed  Google Scholar 

  84. Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240(4):644

    PubMed Central  PubMed  Google Scholar 

  85. Capussotti L, Luca VM, Ferrero A, Tesoriere RL, Ribero D, Polastri R (2007) Timing of resection of liver metastases synchronous to colorectal tumor: proposal of prognosis-based decisional model. Ann Surg Oncol 14(3):1143–1150

    PubMed  Google Scholar 

  86. Pawlik TM, Cosgrove D (2011) The role of peri-operative chemotherapy for resectable colorectal liver metastasis: what does the evidence support? J Gastrointest Surg 15(3):410–415

    PubMed Central  PubMed  Google Scholar 

  87. van Vledder MG, de Jong MC, Pawlik TM, Schulick RD, Diaz LA, Choti MA (2010) Disappearing colorectal liver metastases after chemotherapy: should we be concerned? J Gastrointest Surg 14(11):1691–1700

    PubMed  Google Scholar 

  88. Bischof D, Clary B, Maithel S, Pawlik T (2013) Surgical management of disappearing colorectal liver metastases. Br J Surg 100(11):1414–1420

    CAS  PubMed  Google Scholar 

  89. Bhattacharjya S, Bhattacharjya T, Baber S, Tibballs J, Watkinson A, Davidson B (2004) Prospective study of contrast-enhanced computed tomography, computed tomography during arterioportography, and magnetic resonance imaging for staging colorectal liver metastases for liver resection. Br J Surg 91(10):1361–1369

    CAS  PubMed  Google Scholar 

  90. Kamel IR, Choti MA, Horton KM et al (2003) Surgically staged focal liver lesions: accuracy and reproducibility of dual-phase helical CT for detection and characterization1. Radiology 227(3):752–757

    PubMed  Google Scholar 

  91. Oliva MR, Mortele KJ, Segatto E et al (2006) Computed tomography features of nonalcoholic steatohepatitis with histopathologic correlation. J Comput Assist Tomogr 30(1):37–43

    PubMed  Google Scholar 

  92. Tan MC, Linehan DC, Hawkins WG, Siegel BA, Strasberg SM (2007) Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response. J Gastrointest Surg 11(9):1112–1119

    PubMed  Google Scholar 

  93. Fong Y, Saldinger PF, Akhurst T et al (1999) Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases. Am J Surg 178(4):282–287

    CAS  PubMed  Google Scholar 

  94. van Kessel CS, Buckens CF, van den Bosch MA, van Leeuwen MS, van Hillegersberg R, Verkooijen HM (2012) Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol 19(9):2805–2813

    PubMed Central  PubMed  Google Scholar 

  95. Modlin IM, Oberg K, Chung DC et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9(1):61–72

    CAS  PubMed  Google Scholar 

  96. Frilling A, Modlin IM, Kidd M et al (2014) Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol 15(1):e8–e21

    PubMed  Google Scholar 

  97. Hashim YM, Trinkaus KM, Linehan DC et al (2014) Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs). Ann Surg 259(2):197–203

    PubMed Central  PubMed  Google Scholar 

  98. Chamberlain RS, Canes D, Brown KT et al (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190(4):432–445

    CAS  PubMed  Google Scholar 

  99. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197(1):29–37

    PubMed  Google Scholar 

  100. Mayo SC, de Jong MC, Pulitano C et al (2010) Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol 17(12):3129–3136

    PubMed  Google Scholar 

  101. McEntee G, Nagorney D, Kvols L, Moertel C, Grant C (1990) Cytoreductive hepatic surgery for neuroendocrine tumors. Surgery 108(6):1091–1096

    CAS  PubMed  Google Scholar 

  102. Mayo SC, de Jong MC, Bloomston M et al (2011) Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol 18(13):3657–3665

    PubMed  Google Scholar 

  103. Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46(3):399–424

    Google Scholar 

  104. John BJ, Davidson BR (2012) Treatment options for unresectable neuroendocrine liver metastases. Expert Rev Gastroenterol Hepatol 6(3):357–369

    CAS  PubMed  Google Scholar 

  105. Strosberg J, Gardner N, Kvols L (2009) Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology 89(4):471–476

    CAS  PubMed  Google Scholar 

  106. Givi B, Pommier SJ, Thompson AK, Diggs BS, Pommier RF (2006) Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery 140(6):891–898

    PubMed  Google Scholar 

  107. Ahmed A, Turner G, King B et al (2009) Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer 16(3):885–894

    CAS  PubMed  Google Scholar 

  108. Norlén O, Stålberg P, Öberg K et al (2012) Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg 36(6):1419–1431

    PubMed  Google Scholar 

  109. Capurso G, Rinzivillo M, Bettini R, Boninsegna L, Fave GD, Falconi M (2012) Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. Br J Surg 99(11):1480–1486

    CAS  PubMed  Google Scholar 

  110. Rahman A, Assifi MM, Pedroso FE et al (2012) Is resection equivalent to transplantation for early cirrhotic patients with hepatocellular carcinoma? A meta-analysis. J Gastrointest Surg 16(10):1897–1909

    PubMed  Google Scholar 

  111. Lee KK, Kim DG, Moon IS, Lee MD, Park JH (2010) Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma. J Surg Oncol 101(1):47–53

    PubMed  Google Scholar 

  112. Wu Y-Z, Li B, Wang T, Wang S-J, Zhou Y-M (2011) Radiofrequency ablation vs hepatic resection for solitary colorectal liver metastasis: a meta-analysis. World J Gastroenterol: WJG 17(36):4143

    PubMed Central  PubMed  Google Scholar 

  113. Reuter NP, Woodall CE, Scoggins CR, McMasters KM, Martin RC (2009) Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent? J Gastrointest Surg 13(3):486–491

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Surgical Oncology, John L. Cameron Professor of Alimentary Tract Surgery, Department of Surgery, Johns Hopkins Hospital, 600 N. Wolfe Street, Baltimore, MD, 21287, USA

    Andrew J. Page & Timothy M. Pawlik

  2. Department of Medical Oncology, Johns Hopkins Hospital, Baltimore, MD, USA

    David Cosgrove

Authors
  1. Andrew J. Page
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David Cosgrove
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Timothy M. Pawlik
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Timothy M. Pawlik .

Editor information

Editors and Affiliations

  1. Department of Surgery, Northwestern University, Chicago, Illinois, USA

    Karl Y. Bilimoria

  2. Northwestern University, Chicago, Illinois, USA

    Christina A. Minami

  3. Department of Surgery, Northwestern University, Chicago, Illinois, USA

    David M. Mahvi

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Page, A.J., Cosgrove, D., Pawlik, T.M. (2015). Comparative Effectiveness in Hepatic Malignancies. In: Bilimoria, K., Minami, C., Mahvi, D. (eds) Comparative Effectiveness in Surgical Oncology. Cancer Treatment and Research, vol 164. Springer, Cham. https://doi.org/10.1007/978-3-319-12553-4_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-12553-4_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-12552-7

  • Online ISBN: 978-3-319-12553-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation